Home
About Lectranal®
Research
Product supply
About us
FAQ
News
Events
LECTRANAL® MARKETS
Contact us
EFFICACY AND SAFETY OF LECTRANAL® IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS SYMPTOMS
Pages 1 of 3
Matkovic Z, Zivkovic V, Korica M, Plavec D, Pecanic S, Tudoric N.Efficacy and safety of Astragalus membranaceus in the treatment of patients with seasonal allergic rhinitis. Phytother Res. 2010;24:175-81.


In order to determine efficacy and safety of Lectranal® in the treatment of seasonal allergic rhinitis symptoms, a randomized, double-blind, placebo controlled clinical study was conducted in Dubrava University Hospital in Zagreb.

METHODS

A group of 48 adult patients, each with a history of seasonal allergic rhinitis symptoms caused by pollen and a positive skin prick test for pollen, were enrolled in the study, out of which 41 completed it according to protocol. Patients allergic to a specific pollen were divided into two groups randomly. One group was administered two Lectranal® capsules twice a day and the other received a placebo for a period of 6 weeks during pollen season. The primary and secondary endpoints consisted of the changes observed in the following: a SARS questionnaire (seasonal allergic rhinitis symptoms), a Mini RQLQ (mini rhinoconjunctivitis quality of life questionnaire), a skin-prick test, specific IgE and IgG values, and eosinophilia in nasal secretion. The methods used for safety evaluation included a side effects report, physical examination, and the taking of vital signs.

RESULTS

Overall treatment success
At the end of the trial, the physician and the patients separately evaluated the overall success of the treatment by describing the change in their symptoms as: worse (1), no change(2), little improvement (3), moderate improvement (4), and significant improvement (5). In the Lectranal® group, 78.6% of the patients experienced significant or moderate improvement according to the physician's assessment. In the placebo group, improvement was evaluated by the physician as moderate in 38.5% of the patients. According to the physician, in the placebo group none of the patients had significant improvement, compared to 38.7% of the patients in the Lectranal® group.
Overall treatment effect  after 6 weeks compared to placebo, evaluated by physician (p= 0.017)
Overall treatment effect after 6 weeks compared to placebo, evaluated by physician (p= 0.017)

At the same time, 71.4% of the patients in the Lectranal® group reported significant or moderate improvement, as compared to 53.9% of the patients in the placebo group. None of the patients in the placebo group reported significant improvement, as compared to 35.5% of the patients in the Lectranal® group who evaluated treatment by the highest grade 5 (significant improvement).
Overall treatment effect after 6 weeks compared to placebo, evaluated by patient (p=0,016)
Overall treatment effect after 6 weeks compared to placebo, evaluated by patient (p=0,016)

During the ragweed (Ambrosia artemisifolia) season, the average grade for the efficiency of the treatment was 4.71 for Lectranal®, compared to 3.00 for the placebo, according to the physician's evaluation, and 4.71 and 3.23 respectively for Lectranal® and the placebo, according to the patients' evaluations.
Comparison of overall treatment effect during ragweed season after 6 weeks according to the physician's evaluation (p= 0.0002)
Comparison of overall treatment effect during ragweed season after 6 weeks according to the physician's evaluation (p= 0.0002)
Comparison of overall treatment effect during ragweed season after 6 weeks according to the patients' evaluations (p= 0.001)
Comparison of overall treatment effect during ragweed season after 6 weeks according to the patients' evaluations (p= 0.001)

These results correlate significantly with the reduction in the SARS and Mini RQLQ scores, as well as the reduction in the intensity of the individual symptoms.
  1   |   2   |   3  
RELATED ARTICLES
Preclinical toxicity study on Lectranal®
How does Lectranal® work
Lectranal® and intradermal inflammatory reactions
An assay for immunoglobulines in the blood of mice treated with Lectranal®
Lectranal®, inflammatory reaction, and gene expression in mouse spleen
Disclaimer | General Conditions Of Use | Privacy Statement | Imprint All rights reserved, Lectranal 2006

This website is intended for business to business communication only.
Distributors of the finished products are responsible for ensuring that the claims made
for and use of their products comply with the regulatory requirements of the location.
Owner of the page takes no responsibility for the misuse of the claims.
Design by: Studio2M       Powered by: CorvusCMS